Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer

Prostate

Volumn 74, Issue 3, 2014, Pages 297-305

  Ost, Piet ^a   Decaestecker, Karel ^a   Lambert, Bieke ^a   Fonteyne, Valérie ^a   Delrue, Louke ^a   Lumen, Nicolaas ^a   Ameye, Filip ^b   De Meerleer, Gert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Maria Middelares Hospital   (Belgium)

Author keywords

neoplasm metastasis; oligometastases; prostatic neoplasms; stereotactic body radiotherapy

Indexed keywords

ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; DISTANT METASTASIS; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS DIRECTED THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC SURVIVAL; PROSTATECTOMY; VISCERAL METASTASIS;

EID: 84892439380     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22750     Document Type: Article

References (32)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597.
2. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ,. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: The impact of time from surgery to recurrence. Eur Urol 2011; 59 (6): 893-899.
3. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA,. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up. BJU Int 2012; 109 (1): 32-39.
4. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG,. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: Analysis of the Center for Prostate Disease Research National Database. BJU Int 2011; 108 (3): 378-385.
5. Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT, Committee CRS,. The COMPARE Registry: Design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 2010; 75 (3): 623-629.
6. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59 (4): 572-583.
7. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D,. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171 (3): 1141-1147.
8. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML,. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: A matched cohort study. J Urol 2008; 179 (5): 1830-1837; discussion 1837.
9. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI,. American Society of Clinical O. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25 (12): 1596-1605.
10. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 2010; 57 (1): 49-59.
11. Taylor LG, Canfield SE, Du XL,. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115 (11): 2388-2399.
12. Hellman S, Weichselbaum RR,. Oligometastases. J Clin Oncol 1995; 13 (1): 8-10.
13. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P,. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy. Clin Genitourin Cancer 2013; 11 (1): 27-32.
14. Garcia-Yuste M, Cassivi S, Paleru C,. The number of pulmonary metastases: Influence on practice and outcome. J Thorac Oncol 2010; 5 (6 Suppl 2): S161-S163.
15. Spelt L, Andersson B, Nilsson J, Andersson R,. Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Eur J Surg Oncol 2012; 38 (1): 16-24.
16. Salah S, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K, Al-Haj Ali B,. Colorectal cancer pulmonary oligometastases: Pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 2012; 23 (10): 2649-2655.
17. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ,. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179 (1): 156-161; discussion 161-162.
18. Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT,. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007; 51 (4): 940-947; discussion 947-948.
19. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES,. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013; 24 (11): 2881-2886.
20. Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, De Meerleer G,. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 2011; 60 (4): 842-849.
21. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G,. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008; 72 (3): 799-807.
22. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P,. Is there a favorable subset of patients with prostate cancer who develop oligometastases ? Int J Radiat Oncol Biol Phys 2004; 58 (1): 3-10.
23. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M,. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61 (1): 195-202.
24. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113 (1): 37-49.
25. Furuya Y, Akakura K, Akimoto S, Inomiya H, Ito H,. Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int J Urol 1999; 6 (5): 240-244.
26. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ,. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14 (1): e28-e37.
27. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE,. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010; 16 (12): 1414-1420.
28. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 2012; 72 (2): 527-536.
29. Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knonagel H, Loidl W, Isorna S, Sundaram SK, Collette L, Group EGC,. Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up. Eur Urol 2013; in press. doi: 10.1016/j.eururo.2013.07.024
30. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN,. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59 (1): 51-60.
31. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F,. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline positron emission tomography/computed tomography. Eur Urol 2011; 60 (5): 935-943.
32. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR,. MicroRNA expression characterizes oligometastasis(es). PLoS ONE 2011; 6 (12): e28650.